Home Cart Sign in  
Chemical Structure| 1264-72-8 Chemical Structure| 1264-72-8

Structure of Colistin sulfate
CAS No.: 1264-72-8

Chemical Structure| 1264-72-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Colistin sulfate is a polymyxin antibiotic, a mixture of cyclic polypeptides colistin A and B, effective against most Gram-negative bacilli.

Synonyms: Polymyxin E sulfate; Polymixin E Sulfate

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Colistin sulfate

CAS No. :1264-72-8
SMILES Code : NONE
Synonyms :
Polymyxin E sulfate; Polymixin E Sulfate
MDL No. :MFCD00146495

Safety of Colistin sulfate

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P280-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Acinetobacter baumannii AB5075 1.22 μg/mL 12 h To evaluate the potentiating effect of kaempferol on colistin activity, results showed complete inhibition of bacterial growth when 0.375 mM kaempferol was combined with sub-MIC colistin Commun Biol. 2023 Sep 13;6(1):937.
P. aeruginosa 41782/98 1 μg/mL 24 h Tested susceptibility of Colistin-resistant strain to combination therapy, revealing Colistin's role in disrupting outer membrane for Rifampicin penetration. Antimicrob Agents Chemother. 2023 Apr 18;67(4):e0164122.
P. aeruginosa 19848/85 0.25 μg/mL 24 h Evaluated killing kinetics of Colistin on clinical isolates, demonstrating synergistic bactericidal activity with Rifampicin. Antimicrob Agents Chemother. 2023 Apr 18;67(4):e0164122.
P. aeruginosa PAO1 0.25 μg/mL 24 h Investigated bactericidal effects of Colistin alone and combined with Rifampicin on planktonic P. aeruginosa, showing complete eradication of susceptible strains with combination therapy. Antimicrob Agents Chemother. 2023 Apr 18;67(4):e0164122.
E. cloacae D01 2 μg/ml 24 h Evaluate the synergistic bactericidal effect of Colistin with PFK-158, results showed continuous bacterial elimination within 24 h Antimicrob Agents Chemother. 2019 Jun 24;63(7):e00271-19.
K. pneumoniae H04 2 μg/ml 24 h Evaluate the synergistic bactericidal effect of Colistin with PFK-158, results showed continuous bacterial elimination within 24 h Antimicrob Agents Chemother. 2019 Jun 24;63(7):e00271-19.
E. coli 13-43 2 μg/ml 24 h Evaluate the synergistic bactericidal effect of Colistin with PFK-158, results showed continuous bacterial elimination within 24 h Antimicrob Agents Chemother. 2019 Jun 24;63(7):e00271-19.
Vero cells (monkey kidney epithelial cells) 1 mg/ml 24 h Evaluate cytotoxicity of Colistin, found that combination with Nisin A (2 mg/ml) abolished toxicity Antimicrob Agents Chemother. 2013 Jun;57(6):2719-25.
human peripheral blood leukocytes (PBLs) 550 ng/ml 1 h Assess DNA damage caused by Colistin, observed tail extensions of about 69.29μm Antimicrob Agents Chemother. 2013 Jun;57(6):2719-25.
Klebsiella pneumoniae FADDI-KP035 5 mg/L 72 h Evaluate the bactericidal effect of Colistin monotherapy against K. pneumoniae FADDI-KP035. Results showed no efficacy against the resistant strain. Antimicrob Agents Chemother. 2012 Oct;56(10):5103-12.
Klebsiella pneumoniae FADDI-KP032 0.5, 2, 5 mg/L 72 h Evaluate the bactericidal effect and resistance development of Colistin monotherapy against K. pneumoniae FADDI-KP032. Results showed rapid bacterial killing at low inoculum but poor efficacy at high inoculum with emergence of resistant subpopulations. Antimicrob Agents Chemother. 2012 Oct;56(10):5103-12.
Klebsiella pneumoniae FADDI-KP033 0.5, 2, 5 mg/L 72 h Evaluate the bactericidal effect and resistance development of Colistin monotherapy against K. pneumoniae FADDI-KP033. Results showed rapid bacterial killing at low inoculum but poor efficacy at high inoculum with emergence of resistant subpopulations. Antimicrob Agents Chemother. 2012 Oct;56(10):5103-12.
Klebsiella pneumoniae ATCC 13883 0.5, 2, 5 mg/L 72 h Evaluate the bactericidal effect and resistance development of Colistin monotherapy against K. pneumoniae. Results showed rapid bacterial killing at low inoculum (10^6 CFU/ml) but poor efficacy at high inoculum (10^8 CFU/ml) with emergence of resistant subpopulations. Antimicrob Agents Chemother. 2012 Oct;56(10):5103-12.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
NIH mice Sepsis model Intraperitoneal injection 8 mg/kg Every 12 hours for 48 hours Evaluate the synergistic antimicrobial effect of Ob with Colistin in vivo against resistant strains, showing the combination successfully rescued 80% of the animals. Commun Biol. 2022 Jun 21;5(1):613
Galleria mellonella Infection model Injection 0.08 µg/larva Single dose, observed for 32 hours To evaluate the in vivo efficacy of kaempferol-colistin combination therapy, results showed significant increase in larval survival Commun Biol. 2023 Sep 13;6(1):937.
ICR mice Systemic infection model Intravenous injection 1.3 mg/kg Single dose at 1 hour postinfection Evaluate the in vivo synergistic effect of Colistin with PFK-158, results showed significant improvement in mouse survival rates Antimicrob Agents Chemother. 2019 Jun 24;63(7):e00271-19.
ICR male mice Subcutaneous biofilm infection model Intraperitoneal injection 20 mg/kg Every 12 hours (COL) or 24 hours (LEV/AMI) for 5 days Evaluate the efficacy of COL alone and in combination with other antibiotics on PAO1 and CRPAO1 biofilm infections, results showed that COL combined with amikacin significantly shortened biofilm eradication time, superior to monotherapy Microbiol Spectr. 2022 Oct 26;10(5):e0146822

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00826670 Enterobacteriaceae Infections Phase 4 Completed - Switzerland ... More >> Geneva Universits Hospitals Geneva, Switzerland, 1211 Less <<
NCT03397914 Gram-Negative Bacterial Infect... More >>ions Pediatric Cancer Colistin Colistin Adverse Reaction MIC Less << Phase 4 Recruiting June 2019 Egypt ... More >> Iman Sidhom Recruiting Cairo, Cairo Governorate, Egypt Contact: Yosr Samia Abou Sedira, BCS    201227531255    yosrsamia@gmail.com    Contact: Iman Sidhom, professor       imansidhom@yahoo.com Less <<
NCT02472600 Intestinal Colonization With M... More >>ultidrug-resistant Bacteria Less << Phase 2 Active, not recruiting March 2018 France ... More >> Assistance Publique-Hôpitaux de Paris, Hôpital Beaujon Clichy, France, 92110 Israel Sourasky Medical Center Tel Aviv, Israel Netherlands Universitair Medisch Centrum Utrecht, Utrecht, Netherlands Switzerland Geneva University Hospitals Geneva, Switzerland Less <<
NCT01740947 Colorectal Cancer Phase 4 Terminated(Superiority was no ... More >>longer attainable) Less << - Netherlands ... More >> Slotervaart Ziekenhuis Amsterdam, Netherlands VU University Medical Center Amsterdam, Netherlands Kennemer Gasthuis Haarlem, Netherlands Spaarne Ziekenhuis Hoofddorp, Netherlands WestFries Gasthuis Hoorn, Netherlands Less <<
NCT01798537 Bacteremia Associated With Int... More >>ravascular Line Ventilator Associated Pneumonia Bacteremia Less << Phase 2 Phase 3 Unknown July 2015 Israel ... More >> Rambam Health Care Campus Not yet recruiting Haifa, Israel, 31096 Contact: Yaron P Bar-Lavie, M.D.    ++972-50-206-2027    y_barlavie@rambam.health.gov.il    Contact: Mical Paul, Prof.    ++972-50-206-2140    m_paul@rambam.health.gov.il    Principal Investigator: Yaron P Bar-Lavie, M.D.          Principal Investigator: Mical Paul, Prof. Less <<
NCT01863719 Pathogen Resistance ... More >> Pneumococcal Infection Pneumonia Less << Phase 1 Terminated(Completion of cohor... More >>t 3, safety concerns) Less << - United States, Maryland ... More >> Johns Hopkins Bayview Medical Center - Infectious Diseases Baltimore, Maryland, United States, 21224-2735 United States, Ohio Case Western Reserve University - Case Medical Center - Infectious Disease & HIV Medicine Cleveland, Ohio, United States, 44106-1716 Less <<

References

 

Historical Records

Categories